Clinical Trials Sponsored by Sapientiae Institute

Total 74706 results

National Cancer Institute (NCI)

Enrolling by invitation

Nutrition Intervention Trials in Linxian Follow-up Study

Gastric Cancer | Esophageal Cancer

China
National Cancer Institute (NCI)

Enrolling by invitation

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Cervical Intraepithelial Neoplasia | Oropharyngeal Neoplasms | Squamous Intraepithelial Lesions of the Cervix | Cervical Neoplasms | Hematologic Malignacies

United States
National Cancer Institute (NCI)

Completed

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)

Parents of Children With Cancer | Parents of Children With NF1 | Parents of Children With Neurofibromatosis Type I

United States, Canada
National Cancer Institute (NCI)

Completed

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study

Leukemia | Multiple Myeloma | MGUS | Monoclonal B-Cell Lymphocytosis

United States
National Eye Institute (NEI)

Active, not recruiting

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

Von Hippel-Lindau Disease | Retinal Hemangioblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

COVID-19

United States
National Cancer Institute (NCI)

Enrolling by invitation

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)

United States
National Cancer Institute (NCI)

Active, not recruiting

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Castrate Sensitive Prostate Cancer

United States
National Cancer Institute (NCI)

Enrolling by invitation

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

Multiple Myeloma | Hematologic Malignancies | Leukemia, B-cell | Lyphoma, B-Cell

United States
National Cancer Institute (NCI)

Suspended

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Advanced Solid Tumors | SCLC | HRD Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

Brain Cancer | Brain Tumor | Neoplasm | Spine Cancer | Spine Tumor

United States
National Cancer Institute (NCI)

Enrolling by invitation

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Solid Tumors | Hematologic Malignancies | Pediatric Cancers

United States
National Cancer Institute (NCI)

Active, not recruiting

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Burkitt Lymphoma | Primary Mediastinal Large B-cell Lymphoma | Gray Zone Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Anaplastic Large-Cell Lymphoma

United States
National Cancer Institute (NCI)

Enrolling by invitation

Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

Cancer

United States
National Eye Institute (NEI)

Completed

The Focal Electro-Oculogram in Macular Disease

Age-Related Macular Degeneration | Macular Degeneration

United States
PharmaJet, Inc.
National Cancer Institute (NCI); National Institutes of Health (NIH)

Withdrawn

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Vaccine Reaction

Indonesia
National Cancer Institute (NCI)

Completed

FdCyd and THU for Advanced Solid Tumors

Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial

Cancer | Death

United States
National Cancer Institute (NCI)

Completed

Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

Neurofibroma | Neurofibromatosis Type 1

United States
National Cancer Institute (NCI)

Completed

BRCA Mutations in Latinas

Breast Neoplasms

United States
National Cancer Institute (NCI)

Active, not recruiting

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Prostate Cancer | Neoplasms of Prostate | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
Ottawa Heart Institute Research Corporation
Canadian Institutes of Health Research (CIHR)

Active, not recruiting

Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation (RAFT-PermAF)

Atrial Fibrillation | Heart Disease | Congestive Heart Failure

Canada
National Cancer Institute (NCI)

Completed

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

NSCLC | Solid Tumors | Lymphomas | Granulosa Cell Ovarian Cancer | Metastatic Colon Carcinoma

United States
National Cancer Institute (NCI)

Completed

Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases

Cancer | Brain Metastasis

United States
Mayo Clinic
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Time Longitudinal Study of the Microbiome in Colorectal Cancer Subjects

Gastrointestinal Disease | Cancer Colon

United States
National Cancer Institute (NCI)

Completed

A Nested Case-Control Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners

Lung Cancer

United States
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Suspended

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia

United States
National Eye Institute (NEI)

Completed

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Vertebral Body Sparing Craniospinal Irradiation for Pediatric Patients With Cancer of the Central Nervous System

Malignant Central Nervous System Neoplasm

United States
National Eye Institute (NEI)

Completed

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

Uveitis

United States
National Cancer Institute (NCI)

Completed

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Glioblastoma Multiforme | Gliosarcoma | Giant Cell Glioblastoma | Astrocytoma, Grade IV

United States
National Cancer Institute (NCI)

Terminated

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Mesothelioma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Malignant Neoplasm to Brain

United States
National Cancer Institute (NCI)

Active, not recruiting

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)

Adrenocortical Carcinoma

United States
National Eye Institute (NEI)

Terminated

Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome (VHL3)

Von Hippel-Lindau Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Cause of Familial Testicular Cancer

Testicular Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Small Cell Lung Cancer | Extra-Pulmonary Small Cell Carcinomas

United States
National Cancer Institute (NCI)

Completed

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Refractory Soft Tissue Sarcomas

United States
National Cancer Institute (NCI)

Completed

Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)

Dyskeratosis Congenita | Telomere Biology Disorders

United States
National Cancer Institute (NCI)

Completed

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Burkitt Lymphoma | High-grade B-cell Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | T-cell/Histocyte-rich Large B-cell Lymphoma | Germinal Center B-cell Type (GCB)

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin Lymphoma | Primary Central Nervous System Lymphoma | Gray-zone Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Vulvar, Vaginal, Penile, Rectal Cancer | HPV Positive Cancer

United States
National Cancer Institute (NCI)

Completed

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Glioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IV

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Enrolling by invitation

Efficacy of a Smoke-Free Homes Intervention (SFH 5A RCT)

Cessation, Smoking

United States
National Cancer Institute (NCI)

Completed

LMB-2 to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer | Colorectal Neoplasms | Colorectal Tumors | Colorectal Carcinoma | Colorectal Cancer With Hepatic Metastases

United States
National Cancer Institute (NCI)

Suspended

Rare CNS Tumors Outcomes &Risk

Ependymoma | Medulloblastoma | PNET | High Grade Meningioma | Primary CNS Sarcoma

United States

Clinical Trials Sponsored by Sapientiae Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations